Steven Cohen's PRLD Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 59,168 shares of Prelude Therapeutics Incorporated (PRLD) worth $171,587, representing 0.00% of the portfolio. First purchased in 2020-Q3, this short-term holding has been held for 5 quarters.
Based on 13F filings, Steven Cohen has maintained this position in PRLD for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 59,168 shares. Largest reduction occurred in Q4 2020, reducing 155,690 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Prelude Therapeutics Incorporated (PRLD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Prelude Therapeutics Incorporated (PRLD) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +59,168 | New Buy | 59,168 | $2.90 |
| Q2 2023 | -1,222 | Sold Out | 0 | $0.00 |
| Q1 2023 | +1,222 | New Buy | 1,222 | $5.70 |
| Q4 2020 | -155,690 | Sold Out | 0 | $0.00 |
| Q3 2020 | +155,690 | New Buy | 155,690 | $30.13 |
Steven Cohen's Prelude Therapeutics Incorporated Investment FAQs
Steven Cohen first purchased Prelude Therapeutics Incorporated (PRLD) in Q3 2020, acquiring 155,690 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Prelude Therapeutics Incorporated (PRLD) for 5 quarters since Q3 2020.
Steven Cohen's largest addition to Prelude Therapeutics Incorporated (PRLD) was in Q3 2020, adding 155,690 shares worth $4.69 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 59,168 shares of Prelude Therapeutics Incorporated (PRLD), valued at approximately $171,587.
As of the Q4 2025 filing, Prelude Therapeutics Incorporated (PRLD) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Prelude Therapeutics Incorporated (PRLD) was 155,690 shares, as reported at the end of Q3 2020.